Hana Biosciences announces issuance of Talotrexin patent
Advertisement
Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, announced the issuance of U.S. Patent No. 6,989,386 from the U.S. Patent and Trademark Office. U.S. Patent No. 6,989,386 is directed to Talotrexin compositions and methods of using Talotrexin compositions. The Company believes the patent significantly strengthens its Talotrexin intellectual property estate.
Talotrexin (PT-523) is a novel nonpolyglutamatable antifolate drug which has demonstrated enhanced antitumor activity in a broad spectrum of cancers by targeting DHFR to prevent DNA synthesis and inhibit tumor growth. Compared to currently available antifolates such as methotrexate or pemetrexed (Alimta®; Eli Lilly) in preclinical studies, Talotrexin enters into cells up to 10-times more efficiently, demonstrated 10 to 100 fold more potency by overcoming resistance by remaining active in tumors by not requiring polyglutamation, and binds more tightly to its antitumor target DHFR which enhances efficacy. Thus, a Phase I trial in solid tumors, Phase I/II in NSCLC (non-small cell lung cancer), and a Phase I/II in ALL (acute lymphocytic leukemia) are ongoing. Phase II trials in cervical, endometrial and ovarian cancers are forthcoming.
Other news from the department research and development
